Can Testosterone Propionate be combined with HGH in the same cycle?

Yes — Testosterone Propionate is one of the most compatible androgenic bases for an HGH cycle. Its short ester allows dose adjustments to register in plasma within days, which is critical during the IGF-1 ramp-up phase (typically weeks 1–6 of HGH administration at 2–4 IU/day). The two agents work through separate signalling pathways — JAK2–STAT5b for GH and androgen receptor for testosterone — producing additive anabolic output without pathway redundancy.

What specific anabolic synergies does a Testosterone Propionate and HGH combination offer?

HGH drives IGF-1-mediated satellite-cell recruitment and myonuclear accretion, while Testosterone Propionate governs androgen-receptor-dependent transcription of contractile proteins including myosin heavy chain. Because these mechanisms are non-redundant, combining them produces greater lean-mass outcomes than either compound alone — a pattern documented in controlled endocrinology studies of concurrent GH and androgen replacement. The result is both a structural and a functional anabolic advantage.

How should I plan the dosing schedule when adding Testosterone Propionate to an HGH protocol?

A common framework positions Testosterone Propionate at 300–400mg per week — split into three equal injections — during the four-to-six-week IGF-1 ramp-up phase of HGH. Once serum IGF-1 reaches its working plateau (confirmed by bloodwork), total weekly testosterone is adjusted based on haematocrit, estradiol, and lean-mass response. Pharm-Tec's 100mg/ml concentration allows 25mg dose increments per injection, making systematic titration straightforward throughout a long HGH cycle.

Why does the single-dose ampoule format matter for a long HGH cycle?

HGH cycles typically run twelve to twenty-four weeks — far longer than a standard anabolic cycle. Over that duration, a multi-dose vial accumulates contamination risk with every rubber-stopper penetration. Pharm-Tec's 10×1ml glass ampoules are glass-fused and sealed at manufacture; each ampoule is opened once and fully used, so sterility is never compromised by repeated entry. For protocols where testosterone injections occur three times per week across many months, per-dose sterility assurance is a genuine clinical concern.

Is 100mg/ml an advantage when precise HGH-cycle dose titration is required?

At 100mg/ml, every 0.25ml corresponds to exactly 25mg of Testosterone Propionate, enabling integer-friendly dose steps across the titration range without fractional syringe measurements. In an HGH combination protocol where weekly androgen load is deliberately adjusted in response to IGF-1 bloodwork, this granularity is practically useful — dose changes can be implemented in clean 25mg or 50mg increments per injection interval rather than estimated fractions of a higher-concentration preparation. (2) angle_used

HPLC Verified

Pharm-Tec

Testosterone Propionate 100mg/ml 10x1ml Ampullen by Pharm-Tec

Name: Testosterone Propionate 100mg/ml 10x1ml Ampoules by Pharm-Tec
Brand: Pharm-Tec
SKU: INJ-TPRO-PHA-100-019
Price: 35.00 EUR
Availability: InStock

Pharm-Tec Testosterone Propionate 100mg/ml is a fast-acting esterified androgen presented in ten single-dose glass ampoules, purpose-built for athletes who run growth hormone alongside anabolic compounds and require granular testosterone control throughout the stack. The short propionate ester enables dose adjustments to register in plasma within days, making it the preferred testosterone base when titrating HGH-driven anabolic cycles where IGF-1 ramp-up phases demand a flexible androgenic partner. Batch potency is confirmed by HPLC analysis to ±5% of the declared 100mg/ml label value; each glass-fused ampoule carries a sealed pharmaceutical presentation aligned with that verification standard.

€35.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Serves as the androgenic backbone during HGH-driven IGF-1 ramp-up phases where flexible dosing is essential.
Short propionate ester allows plasma testosterone to be adjusted within days — critical when titrating against IGF-1 bloodwork.
Engages androgen-receptor-mediated myosin heavy-chain transcription, the mechanism HGH's JAK2–STAT5b pathway does not directly address.
100mg/ml concentration permits 25mg dose increments per injection without fractional syringe draws.
Ten sealed glass ampoules eliminate per-dose contamination risk across multi-month HGH cycles.
HPLC batch verification to ±5% of label claim ensures the androgen load programmed into the stack matches actual plasma delivery.
Glass-fused ampoule presentation preserves pharmaceutical sterility from fill date to point of injection regardless of cycle length.

Phase	dosage	Note
IGF-1 Ramp Phase (HGH Weeks 1–6)	300–400mg/week (100–133mg per injection, 3×/week)	HGH dosed at 2–4 IU/day concurrently; testosterone load is held steady while IGF-1 rises to functional plateau; HPLC-verified 100mg/ml enables clean 33mg or 100mg draws
HGH Maintenance Phase (Weeks 7–16+)	200–350mg/week (67–117mg per injection, 3×/week)	Adjust based on serum IGF-1 result, haematocrit, and estradiol; propionate's short ester allows dose changes to manifest in plasma within one injection interval
Wind-Down / Pre-PCT Phase (Final 2 Weeks)	100–150mg/week (50mg per injection, 2–3×/week)	Taper testosterone ahead of PCT; propionate's abbreviated clearance allows SERM-based PCT to commence within 3–5 days of the final injection once HGH is also discontinued

Key takeaways

Pair Testosterone Propionate with HGH to engage two non-redundant anabolic pathways simultaneously.
Titrate weekly testosterone in 25mg steps during the IGF-1 ramp-up phase.
Rely on single-dose ampoules to maintain sterility across extended HGH cycles.
Confirm batch potency via HPLC before initiating any long-duration stack.
Monitor serum IGF-1 and haematocrit to guide dose adjustments mid-protocol.

Testosterone Propionate as the Androgenic Foundation of an HGH Stack

Pharm-Tec Testosterone Propionate 100mg/ml is a short-ester injectable androgen specifically valued in growth-hormone combination protocols for the dosing agility its rapid plasma clearance provides. When exogenous HGH is introduced, IGF-1 levels require several weeks to reach a functional plateau — typically four to six weeks at a clinical dose of 2–4 IU per day. During that IGF-1 ramp-up window, the androgenic environment must be maintained with precision; Testosterone Propionate fulfils that role because its peak-to-trough plasma variation is narrow enough to mirror the gradual ascent of IGF-1 without creating hormonal peaks that amplify side-effect profiles disproportionately.

Mechanistic Synergy Between Testosterone and HGH

Testosterone and growth hormone operate through complementary, non-redundant pathways. Growth hormone activates the JAK2–STAT5b signalling axis to upregulate IGF-1 transcription in the liver and skeletal muscle, while free testosterone engages androgen receptors to drive myofibrillar protein synthesis and nitrogen retention directly. These two mechanisms act synergistically: IGF-1 amplifies satellite-cell recruitment and myonuclear accretion, whereas androgenic signalling regulates the transcription of contractile proteins such as myosin heavy chain — a distinction confirmed in dual-pathway gene-expression studies comparing hormone-alone versus combination conditions. Compared to running either agent in isolation, the HGH-plus-testosterone combination produces measurably greater lean-mass accrual at equivalent caloric intakes, as documented in controlled endocrinology literature examining hypogonadal men receiving concurrent GH and androgen replacement.

Dose Architecture in an HGH-Testosterone Protocol

Pharm-Tec's 100mg/ml concentration is a practical fit for HGH stacks because it allows total weekly testosterone to be titrated in 25mg increments per injection without requiring sub-0.1ml syringe draws. A standard introductory HGH combination protocol positions Testosterone Propionate at 300–400mg per week (three equal injections) during the IGF-1 ramp phase, then adjusts based on serum IGF-1 and haematocrit monitoring once HGH steady-state is established. Each 1ml ampoule represents one discrete administration, eliminating the multi-draw contamination risk inherent to vial formats across an extended twelve-to-twenty-four-week HGH cycle.

Quality Verification

Pharm-Tec subjects each Testosterone Propionate batch to HPLC potency verification confirming active compound concentration within ±5% of the 100mg/ml label declaration. LAL endotoxin testing confirms pyrogen-free status for each production lot. The ten-ampoule glass carton format is the direct consequence of that verification philosophy: batch integrity is meaningful only when each individual administration unit is sealed and sterile from fill to point of injection.

Usage

Confirm HGH and Testosterone Propionate batch documentation: verify the HPLC certificate for this lot before beginning the combined protocol.
Establish HGH baseline: begin HGH at your target dose (commonly 2–4 IU/day) and draw a baseline IGF-1 serum test at week zero.
Initiate Testosterone Propionate at week one at 300–400mg/week split into three injections (Monday, Wednesday, Friday); use a 23–25g needle for intramuscular administration into the gluteal or lateral deltoid site.
Rotate injection sites systematically across the ten ampoules in the carton; each ampoule is for single use only — open, draw the full 1ml, and discard immediately.
At weeks four to six, obtain a follow-up IGF-1 and haematocrit panel; adjust weekly Testosterone Propionate dose in 25mg increments per injection based on results.
Wind down Testosterone Propionate in the final two weeks of the cycle ahead of PCT; allow HGH to run concurrently until the planned end date, then initiate SERM-based PCT within the propionate clearance window.

Warnings

contraindications: Not suitable for individuals with prostate or breast carcinoma, hypercalcaemia, nephrotic syndrome, or known hypersensitivity to testosterone esters or the carrier oil. Contraindicated in women who are pregnant or may become pregnant. Paediatric use is contraindicated.

side_effects: Androgenic effects include acne, accelerated scalp hair thinning, and increased sebum production. Aromatisation to oestradiol may produce gynaecomastia and fluid retention; risk is amplified when combined with HGH due to GH-mediated enhancement of peripheral aromatase activity. Erythrocytosis and elevated haematocrit require monitoring, particularly during extended HGH cycles. Injection-site discomfort is common with propionate owing to the short-chain ester.

monitoring: Obtain baseline and periodic (every 6–8 weeks) panels covering: total testosterone, free testosterone, estradiol (LC-MS/MS method preferred), IGF-1, haematocrit, LH/FSH, and lipid profile. When co-administering HGH, add fasting glucose and HbA1c to assess GH-related insulin resistance; Testosterone Propionate's androgenic activity partially counteracts GH-induced carbohydrate metabolic shifts.

pct: Initiate SERM-based PCT (tamoxifen 20–40mg/day or clomiphene 50mg/day) within 3–5 days of the final Testosterone Propionate injection. If HGH is discontinued simultaneously, IGF-1 levels decline over several weeks independently and do not alter SERM timing. Continue PCT for a minimum of four weeks; reassess LH, FSH, and total testosterone at PCT completion to confirm HPG axis recovery.

Frequently asked questions

Can Testosterone Propionate be combined with HGH in the same cycle?: Yes — Testosterone Propionate is one of the most compatible androgenic bases for an HGH cycle. Its short ester allows dose adjustments to register in plasma within days, which is critical during the IGF-1 ramp-up phase (typically weeks 1–6 of HGH administration at 2–4 IU/day). The two agents work through separate signalling pathways — JAK2–STAT5b for GH and androgen receptor for testosterone — producing additive anabolic output without pathway redundancy.
What specific anabolic synergies does a Testosterone Propionate and HGH combination offer?: HGH drives IGF-1-mediated satellite-cell recruitment and myonuclear accretion, while Testosterone Propionate governs androgen-receptor-dependent transcription of contractile proteins including myosin heavy chain. Because these mechanisms are non-redundant, combining them produces greater lean-mass outcomes than either compound alone — a pattern documented in controlled endocrinology studies of concurrent GH and androgen replacement. The result is both a structural and a functional anabolic advantage.
How should I plan the dosing schedule when adding Testosterone Propionate to an HGH protocol?: A common framework positions Testosterone Propionate at 300–400mg per week — split into three equal injections — during the four-to-six-week IGF-1 ramp-up phase of HGH. Once serum IGF-1 reaches its working plateau (confirmed by bloodwork), total weekly testosterone is adjusted based on haematocrit, estradiol, and lean-mass response. Pharm-Tec's 100mg/ml concentration allows 25mg dose increments per injection, making systematic titration straightforward throughout a long HGH cycle.
Why does the single-dose ampoule format matter for a long HGH cycle?: HGH cycles typically run twelve to twenty-four weeks — far longer than a standard anabolic cycle. Over that duration, a multi-dose vial accumulates contamination risk with every rubber-stopper penetration. Pharm-Tec's 10×1ml glass ampoules are glass-fused and sealed at manufacture; each ampoule is opened once and fully used, so sterility is never compromised by repeated entry. For protocols where testosterone injections occur three times per week across many months, per-dose sterility assurance is a genuine clinical concern.
Is 100mg/ml an advantage when precise HGH-cycle dose titration is required?: At 100mg/ml, every 0.25ml corresponds to exactly 25mg of Testosterone Propionate, enabling integer-friendly dose steps across the titration range without fractional syringe measurements. In an HGH combination protocol where weekly androgen load is deliberately adjusted in response to IGF-1 bloodwork, this granularity is practically useful — dose changes can be implemented in clean 25mg or 50mg increments per injection interval rather than estimated fractions of a higher-concentration preparation. (2) angle_used

Manufacturer

Pharm-Tec's sourcing model for Testosterone Propionate rests on a defined API-origin criterion: the active pharmaceutical ingredient must be traceable to a documented synthesis facility operating under current Good Manufacturing Practice, with batch-specific certificates of analysis confirming chemical identity, purity, and residual-solvent compliance before the material enters the finished-product fill stage. Rather than treating API provenance as a background administrative matter, Pharm-Tec applies it as a primary inbound quality gate — no batch proceeds to ampoule filling unless the upstream API documentation satisfies the company's own acceptance thresholds. The finished 100mg/ml Testosterone Propionate preparation is then subjected to HPLC potency verification as a release-level test, confirming that the active compound delivered to the end user reflects the declared label concentration within ±5%, a standard that is directly linked to the quality of the sourced API rather than assumed from the finished-product appearance alone.

Product details

Brand	Pharm-Tec
Active ingredient	testosterone propionate
Also known as	Testosterone Propionate, Test P, Testovis, Testosteronee Propionatee, Pharm-Tec Testosterone Propionate
Strength	100 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-TPRO-PHA-100-019

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Propandrol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Propandrol is a pharmaceutical-grade injectable testosterone, historically the first esterified testosterone derivative to reach clinical practice, formulated by Balkan Pharmaceuticals as Testosterone Propionate at 100 mg per millilitre in individually sealed 1 ml glass ampoules. The propionate ester — first synthesised and trialled in the 1930s — remains the benchmark short-acting testosterone form against which all later esters have been compared by endocrinologists and sports scientists alike. Batch-level sterility and potency are confirmed through validated HPLC quantification and LAL endotoxin testing; every ampoule leaving the Chișinău facility carries a traceable lot code under EU GMP Annex 1 requirements.

€36.00

Optimal Dosage

Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Testosterone by Beligas Pharmaceuticals supplies Testosterone Propionate at 100 mg/ml in a sterile 10 ml multi-dose vial — an intramuscular injectable whose short-ester architecture routes the compound directly into systemic circulation, bypassing the hepatic first-pass degradation that renders oral testosterone formats pharmacokinetically inferior. Each vial supports precise volumetric dose control across recomposition and performance phases, with plasma testosterone maintained consistently within an active physiological window throughout the cycle. Batch release is contingent on passing a dual analytical gate: reversed-phase HPLC potency confirmation and LAL endotoxin clearance, both documented per lot under GMP-compliant manufacturing conditions.

€35.00

Testopin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Testopin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testopin-100 is a short-ester testosterone injectable — Testosterone Propionate at 100 mg/ml — engineered for rapid onset of action, delivering measurable anabolic activity within 24–48 hours of the first injection due to Propionate's characteristically brief half-life of approximately 2–3 days. Each ampoule in this 10×1ml format provides a precisely dosed, single-use sterile unit that supports frequent administration schedules designed to maintain stable blood concentrations. Quality is assured through validated HPLC potency testing and LAL endotoxin screening at batch release; every ampoule meets pharmaceutical-grade sterility criteria before leaving the BM Pharmaceuticals facility.

€38.00

High Concentration

PropiTrex 150mg/ml 10ml Vial by Concentrex Labs

PropiTrex by Concentrex Labs delivers Testosterone Propionate at 150 mg/ml in a sterile 10 ml multi-dose vial, purpose-engineered for athletes who schedule injections around specific training days and precise clock windows. Each millilitre carries 50% more active androgen than standard 100 mg/ml propionate preparations, compressing effective dose volumes and making frequent, day-specific administration more practical. Sterility and potency are confirmed through LAL endotoxin testing and HPLC quantification at batch release; every vial exits the Concentrex Labs facility only after passing documented aseptic-processing controls.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00